年报虚假记载、连续五年存重大遗漏，香雪制药难 逃"ST" 广州市香雪制药股份有限公司（以下简称香雪制药）披露的最新公告，让公司持续数年的年报虚假记 载、因未按规定披露关联方非经营性资金占用导致的重大遗漏等事项有了初步结果，根据证监会广东监 管局发出的《行政处罚事先告知书》，香雪制药及多位高管拟被处以合计2065万元罚款，实控人王永辉 拟被采取5年市场禁入措施，公司股票简称也将从3月25日起变更为"ST香雪"。香雪制药的"雷"不止于 此，高企的负债率和连年亏损的业绩，都让这家企业举步维艰。 连续五年年报存在重大遗漏 3月24日，香雪制药披露，近日收到证监会广东监管局发出的《行政处罚事先告知书》，公司及实控人 王永辉涉嫌信息披露违法违规一案，已调查完毕，并拟作出行政处罚。早在2024年9月30日，香雪制药 及王永辉收到证监会下发的《立案告知书》，公司及王永辉被证监会立案。 此外，由于未按规定披露关联方非经营性资金占用，香雪制药2016年至2020年年度报告存在重大遗漏， 主要涉及香雪制药控股股东广州市昆仑投资有限公司（以下简称昆仑投资）等。 具体来看，2016年至2020年，香雪制药以购买信托理财、中药材合作经营 ...

3月24日，香雪制药（300147.SZ）公告称，公司及相关当事人收到中国证监会广东监管局的《行政 处罚事先告知书》。香雪制药及王永辉、卢锋、陈炳华、黄滨、徐力、郝世明等人拟被罚合计2075万 元，其中王永辉违法情节严重，被采取5年证券市场禁入措施。 同日，香雪制药还发布了另外一份公告称，根据《深圳证券交易所创业板股票上市规则》第9.4条 规定，公司股票交易将被实施其他风险警示。公司股票自2025年3月25日（星期二）被实施其他风险警 示，股票简称由"香雪制药"变更为"ST香雪"。 公告显示，2019年12月，香雪制药位于广州生物岛上5栋别墅被相关政府部门拆除，香雪制药未按 规定确认拆除别墅产生的在建工程损失，导致2019年年度报告虚增利润5383.25万元，占当期披露利润 总额的45.98%，2019年年度报告存在虚假记载。 此外，2016年至2020年，香雪制药以购买信托理财、中药材合作经营等名义支出款项，并最终划转 至控股股东广州市昆仑投资有限公司等关联方，用于关联方偿还借款、收购股权等。2018年至2020年， 香雪制药代关联方广州香岚健康产业有限公司支付香岚官洲酒店工程款。 香雪制药及相关人员拟被罚 ...

Key Points - The article emphasizes the Chinese government's commitment to implementing proactive macro policies to support economic stability and growth, including potential new policies if necessary [2] - The article highlights the importance of enhancing the business environment for various enterprises through economic reforms and addressing bottlenecks in economic circulation [2] - The article discusses the upcoming significant events in the global market, including earnings reports from major companies and important economic data releases [4] Macro - Premier Li Qiang met with U.S. senators, stating that trade wars yield no winners and emphasizing the need for cooperation to address trade imbalances [6] - Vice Premier He Lifeng welcomed multinational companies to invest in China, highlighting the resilience and potential of the Chinese economy [6] - The government plans to deepen supply-side structural reforms and regulate competition to promote high-quality development [6] Domestic Stock Market - CITIC Securities identified two critical time points for the market: the first in early April when external risks are expected to materialize, and the second mid-year when U.S. economic and policy cycles may align with China's [9] - The "Leading Enterprise" action plan in Guangzhou aims to enhance the integration of industry and capital, promoting more competitive companies to go public [9] - The report notes a significant increase in new account openings at several securities firms, indicating growing market participation [10] Financial - A surge in the number of funds focusing on free cash flow indicates a market trend towards financial health metrics, driven by demand and policy direction [14] - The head of the Industrial and Commercial Bank of China emphasized the shift from a capital-centric to a technology-centric financial service model [14] Real Estate - Suggestions were made to stabilize asset prices and improve income levels to boost consumer spending, particularly in real estate and equity markets [17] Industry - XPeng Motors' chairman discussed the future of high-level autonomous driving technology, predicting significant advancements in the coming years [19] - The Henan province announced plans for extensive 5G infrastructure development, aiming for over 270,000 5G base stations in the next three years [19] Overseas - The WTO Director-General highlighted the U.S. as a major beneficiary of global trade, countering claims of trade disadvantages [21] - The UK government plans to invest £600 million to address skill shortages in the construction sector, crucial for housing development [22] International Stock Market - SpaceX aims to achieve a weekly launch frequency for its Starship within a year, enhancing its operational capabilities [23] Commodity - The China Iron and Steel Association noted that supply-demand imbalances are a key issue in the industry, advocating for the closure of new production capacity [26] - Methanol port inventories have decreased, indicating a market shift towards destocking [26] - BHP's CEO projected a significant copper supply gap in the next decade, emphasizing the need for substantial investment in mining [26] Bonds - The government plans to issue long-term special bonds to support various initiatives, with a focus on local government debt management [28] - The AI and robotics sectors are identified as key drivers of market growth, with expectations for increased investment opportunities [28]

Core Viewpoint - Xiangxue Pharmaceutical has been penalized for information disclosure violations, leading to a warning and fines for its actual controller, Wang Yonghui, and other executives, while the company's stock has been marked with risk warnings due to false financial reporting [2][6]. Summary by Sections Company Penalties and Stock Status - On March 23, Xiangxue Pharmaceutical announced that Wang Yonghui received a warning and a fine of 10 million yuan, with several others also penalized. The company's stock will be marked with risk warnings, changing its name to "ST Xiangxue" while retaining the stock code "300147" [2]. - The stock will be suspended for one day starting March 24, 2025, and will resume trading on March 25, 2025 [2]. Violations and Financial Misreporting - The company was found to have false records in its 2019 annual report, which inflated profits by 53.83 million yuan, accounting for 45.98% of the total reported profit for that year [3]. - From 2016 to 2020, Xiangxue Pharmaceutical failed to disclose significant non-operating fund occupations involving related parties, with amounts of 585 million yuan, 845 million yuan, 1.408 billion yuan, 657 million yuan, and 1.357 billion yuan respectively [4]. Related Party Transactions - The company engaged in transactions that resulted in non-operating fund occupations, with undisclosed amounts in annual reports from 2016 to 2019, only revealing 1.262 billion yuan in the 2020 report [4][5]. - The undisclosed fund occupations represented significant percentages of the company's net assets, ranging from 2.22% to 38.79% across the years [4][5]. Management Accountability - Wang Yonghui was identified as the organizer of the fund occupation activities, leading to penalties for him and other executives, with fines ranging from 150,000 to 2 million yuan [6].

广州市香雪制药股份有限公司（以下简称"公司"）及公司实际控制人王永 辉于 2024 年 9 月 30 日收到中国证券监督管理委员会（以下简称"中国证监会"） 下发的《立案告知书》（编号：证监会立案字 0062024028 号、编号：证监会立 案字 0062024029 号）。公司及王永辉因涉嫌信息披露违法违规，根据《中华人 民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定 对公司及王永辉立案。具体内容详见公司于 2024 年 9 月 30 日在巨潮资讯网披露 的《关于公司及实际控制人收到中国证券监督管理委员会立案告知书的公告》 （2024-051）。 证券代码:300147 证券简称: 香雪制药 公告编号:2025-004 广州市香雪制药股份有限公司 关于公司及相关当事人收到《行政处罚事先告知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 3 月 21 日，公司收到中国证监会发出的《行政处罚事先告知书》（广 东证监处罚字〔2025〕5 号），现将具体情况公告如下： 一、《行政处罚事先告知书》具体内容 广州市香雪制 ...

证券代码：300147 证券简称：香雪制药 公告编号：2025-005 广州市香雪制药股份有限公司 关于公司股票交易将被实施其他风险警示 暨股票停复牌的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、2025 年 3 月 21 日，广州市香雪制药股份有限公司（以下简称"公司"） 收到中国证券监督管理委员会（以下简称"中国证监会"）发出的《行政处罚事 先告知书》（广东证监处罚字〔2025〕5 号）。根据《深圳证券交易所创业板股票 上市规则》第 9.4 条规定："上市公司出现下列情形之一的，本所对其股票交易 实施其他风险警示：（七）根据中国证监会行政处罚事先告知书载明的事实，公 司披露的年度报告财务指标存在虚假记载，但未触及第 10.5.2 条第一款规定情 形，前述财务指标包括营业收入、利润总额、净利润、资产负债表中的资产或者 负债科目"，公司股票交易将被实施其他风险警示。 2、公司股票自 2025 年 3 月 24 日（星期一）开市起停牌 1 天，将于 2025 年 3 月 25 日（星期二）开市起复牌。 3、公司股票自 2025 年 ...

证券代码:300147 证券简称:香雪制药 公告编号:2025—003 广州市香雪制药股份有限公司 关于被债权人申请预重整的专项自查报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）于近日收到债权人广东 景龙建设集团有限公司（以下简称"景龙建设"）送达的《告知函》，其以公司 未履行生效法律文书、不能清偿到期债务，明显缺乏清偿能力，但具有重整价值 及重整的可行性为由，于近日向广州市中级人民法院（以下简称"法院"）申请 对公司进行预重整。法院就景龙建设的申请对公司出具了（2025）粤 01 破申 54 -2 号《通知书》。具体详见公司于本报告同日披露在巨潮资讯网（www.cninfo. com.cn）《关于被债权人申请预重整的提示性公告》。截至本报告披露日，公司 尚未收到法院关于启动预重整程序或受理重整申请的相关法律文书，申请人的申 请能否被法院裁定受理以及具体受理时间存在不确定性。 根据《深圳证券交易所上市公司自律监管指引第 14 号——破产重整等事项》 的相关规定，公司对是否涉及被深圳证券交易所强制退市行为的情 ...

证券代码:300147 证券简称:香雪制药 公告编号:2025—002 广州市香雪制药股份有限公司 关于被债权人申请预重整的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.广州市香雪制药股份有限公司（以下简称"公司"）于近日收到债权人广 东景龙建设集团有限公司（以下简称"景龙建设"）送达的《告知函》，其以公 司未履行生效法律文书、不能清偿到期债务，明显缺乏清偿能力，但具有重整价 值及重整的可行性为由，于近日向广州市中级人民法院（以下简称"法院"）申 请对公司进行预重整。法院就景龙建设的申请对公司出具了（2025）粤 01 破申 54-2 号《通知书》。 2.截至本公告披露日，公司尚未收到法院启动预重整或受理预重整申请的文 件，预重整申请能否被法院裁定受理，公司是否会进入预重整及重整程序，尚存 在不确定性，预重整或重整是否成功也存在不确定性。即使法院决定受理预重整 申请，也不代表公司正式进入重整程序。在预重整程序中，法院将依法审查是否 受理重整申请，公司能否进入重整程序尚存在不确定性。公司将及时披露有关事 项的进展情况，敬请广大投资者 ...

Financial Performance Expectations - The company expects a net profit loss between CNY 59,961 million and CNY 86,243 million for the fiscal year 2024, representing a decline of 54.15% to 121.73% compared to the previous year's loss of CNY 38,896 million[3]. - The expected net profit loss after deducting non-recurring gains and losses is projected to be between CNY 57,094 million and CNY 83,377 million, a decrease of 65.75% to 142.05% from last year's loss of CNY 34,446 million[3]. - Total operating revenue is anticipated to be between CNY 161,317 million and CNY 201,317 million, down from CNY 229,929 million in the previous year[3]. Financial Expenses and Impairments - Financial expenses are estimated to be approximately CNY 23,000 million due to significant short-term and long-term borrowings[6]. - Fixed asset depreciation and amortization are expected to impact the company by about CNY 19,000 million[7]. - The company anticipates asset impairment provisions totaling approximately CNY 30,800 million for inventory, construction in progress, fixed assets, and development expenditures[7]. - Other operating expenses related to litigation and overdue interest are projected to be around CNY 8,300 million[8]. - The impact of non-recurring gains and losses on net profit is estimated to be about CNY 2,900 million[9]. Business Outlook - The overall business situation of the company is currently normal, and the impairment amounts are preliminary estimates subject to further evaluation and audit[10]. - The company aims to enhance profitability and achieve sustainable and stable operations moving forward[10].

证券代码:300147 证券简称:香雪制药 公告编号:2024-065 广州市香雪制药股份有限公司 2024 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决议案的情况。 2、本次股东会采取现场投票与网络投票表决相结合的方式召开。 一、会议召开和出席情况 1、广州市香雪制药股份有限公司（以下简称"公司"）于 2024 年 12 月 14 日以公告形式发出《广州市香雪制药股份有限公司关于召开 2024 年第二次临时 股东会的通知》。 公司部分现任董事、监事、高级管理人员和公司聘请的见证律师等相关人士 出席了会议。北京大成（广州）律师事务所吕晖律师和张秀婷律师见证了本次股 东会并出具了法律意见书。 （2）现场会议出席情况 2、会议召开方式：本次股东会采取现场投票与网络投票表决相结合的方式。 3、会议召开日期和时间 现场会议召开日期和时间：2024 年 12 月 30 日（星期一）上午 10:00 网络投票日期和时间：2024 年 12 月 30 日。其中，通过深圳证券交易所交 易系统进行网络投票的时 ...